With our in vitro and in vivo assays, we demonstrated that miR-4500-mediated RRM2 downregulation inhibits proliferation, angiogenesis, invasion, and migration of breast cancer cells and promotes apoptosis through inhibition of MAPK signaling pathway activation (Figure 10). The gene discussed is RRM2; the disease is breast carcinoma.